NEWARK, Calif., June 15, 2021
/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a
clinical stage biopharmaceutical company, today announced the
pricing of its previously announced underwritten public offering of
3,046,358 shares of its common stock at a price to the public of
$37.75 per share. Gross proceeds to
Protagonist from the offering are expected to be approximately
$115 million, before deducting
underwriting discounts and commissions and offering expenses. All
of the shares of common stock are being offered by Protagonist. In
connection with this offering, Protagonist has granted the
underwriters a 30-day option to purchase up to 456,953 additional
shares of its common stock at the public offering price less
underwriting discounts and commissions.
J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler are acting as joint book-running
managers for the offering. JMP Securities LLC and H.C. Wainwright
& Co., LLC are acting as co-lead managers for the offering. The
offering is expected to close on or about June 18, 2021, subject to satisfaction of
customary closing conditions.
A shelf registration statement relating to the offered shares of
common stock was filed with the Securities and Exchange Commission
(SEC) on December 10, 2020. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering have been filed with the SEC and a final
prospectus supplement and accompanying prospectus related to the
offering will be filed with the SEC and will be available on the
SEC's website, located at www.sec.gov. The offering is being made
only by means of a prospectus supplement and accompanying
prospectus. Copies of the prospectus supplement and the
accompanying prospectus related to the offering may be obtained,
when available, from J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at
866-803-9204, or by email at prospectus-eq_fi@jpmchase.com;
Jefferies LLC (Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York,
New York 10022; telephone: 877-821-7388; email:
Prospectus_Department@Jefferies.com); or Piper Sandler & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800)
747-3924 or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. Protagonist is headquartered in Newark, California.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding Protagonist's expectations regarding the
completion and timing of the public offering. In some cases, you
can identify these statements by forward-looking words such as
"expect," "may," "will," or the negative or plural of these words
or similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances). These
forward-looking statements are based on Protagonist's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the
public offering. There can be no assurance that Protagonist
will be able to complete the public offering on the anticipated
terms, or at all. Additional information concerning these and
other risks can be found in Protagonist's periodic filings with the
SEC, including under the heading "Risk Factors" contained therein,
as well as the risks identified in the registration statement and
the preliminary prospectus supplement relating to the
offering. Any forward-looking statements that Protagonist
makes in this press release speak only as of the date of this press
release. Except as required by law, Protagonist assumes no
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-pricing-of-115-million-upsized-public-offering-of-common-stock-301313242.html
SOURCE Protagonist Therapeutics, Inc.